CRD 5
Alternative Names: CRD5Latest Information Update: 11 Sep 2019
At a glance
- Originator Liponex
- Developer Liponex; University of Ottawa Heart Institute
- Class Antihyperlipidaemics
- Mechanism of Action Apolipoprotein A-I stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Dyslipidaemias
Most Recent Events
- 20 Jul 2007 CRD 5 is available for licensing worldwide (http://www.liponex.ca)
- 18 Jul 2007 Preclinical trials in Dyslipidaemias in Canada (PO)
- 13 Apr 2007 Results from a phase I/II clinical trial in patients with Dyslipidaemia added to the adverse events and Hyperlipidaemia therapeutic trials sections